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This study showed a metastasis-suppressive function of
sterile a motif– and Src-homology 3–domain containing 1
(SASH1) in vivo. Furthermore, SASH1 antagonizes
epithelial–mesenchymal transition, tumor aggressiveness,
and chemoresistance in colon cancer. Mechanistically,
SASH1 directly inhibits the oncoprotein V-Crk avian sarcoma
virus CT10 oncogene homolog-like, introduced as its new
interaction partner.
BACKGROUND & AIMS: The tumor-suppressor sterile a motif–
and Src-homology 3–domain containing 1 (SASH1) has clinical
relevance in colorectal carcinoma and is associated speciﬁcally
with metachronous metastasis. We sought to identify the mo-
lecular mechanisms linking decreased SASH1 expression with
distant metastasis formation.
METHODS: SASH1-deﬁcient, SASH1-depleted, or SASH1-
overexpressing HCT116 colon cancer cells were generatedby the Clustered Regularly Interspaced Short Palindromic
Repeats/CRISPR-associated 9-method, RNA interference, and
transient plasmid transfection, respectively. Epithelial-
mesenchymal transition (EMT) was analyzed by quantitative
reverse-transcription polymerase chain reaction, immunoblot-
ting, immunoﬂuorescence microscopy, migration/invasion
assays, and 3-dimensional cell culture. Yeast 2-hybrid assays and
co-immunoprecipitation/mass-spectrometry showed V-Crk
avian sarcoma virus CT10 oncogene homolog-like (CRKL) as a
novel interaction partner of SASH1, further conﬁrmed by domain
mapping, site-directed mutagenesis, co-immunoprecipitation,
and dynamic mass redistribution assays. CRKL-deﬁcient cells
were generated in parental or SASH1-deﬁcient cells. Metastatic
capacity was analyzed with an orthotopic mouse model.
Expression and signiﬁcance of SASH1 and CRKL for survival and
response to chemotherapy was assessed in patient samples from
our department and The Cancer Genome Atlas data set.
RESULTS: SASH1 expression is down-regulated during
cytokine-induced EMT in cell lines from colorectal, pancreatic,
or hepatocellular cancer, mediated by the putative SASH1
promoter. Deﬁciency or knock-down of SASH1 induces EMT,
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chemoresistance. SASH1 counteracts EMT through interaction
with the oncoprotein CRKL, inhibiting CRKL-mediated activa-
tion of SRC kinase, which is crucially required for EMT. SASH1-
deﬁcient cells form signiﬁcantly more metastases in vivo,
depending entirely on CRKL. Patient tumor samples show
signiﬁcantly decreased SASH1 and increased CRKL expression,
associated with signiﬁcantly decreased overall survival. Pa-
tients with increased CRKL expression show signiﬁcantly worse
response to adjuvant chemotherapy.
CONCLUSIONS: We propose SASH1 as an inhibitor of CRKL-
mediated SRC signaling, introducing a potentially druggable
mechanism counteracting chemoresistance and metastasis
formation. (Cell Mol Gastroenterol Hepatol 2019;7:33–53;
https://doi.org/10.1016/j.jcmgh.2018.08.007)
Keywords: EMT; Tumor Suppressor; SRC-Kinase;
Chemoresistance.
ost cancer-related deaths can be attributed toAbbreviations used in this paper: BSA, bovine serum albumin; cDNA,
complementary DNA; CRISPR/Cas9, Clustered Regularly Interspaced
Short Palindromic Repeats/CRISPR-associated 9; CRKL, V-Crk avian
sarcoma virus CT10 oncogene homolog-like; DMEM, Dulbecco’s
modiﬁed Eagle medium; EMT, epithelial-mesenchymal transition; GFP,
green ﬂuorescent protein; gRNA, guide RNA; GTPase, guanosine tri-
phosphatase; mRNA, messenger RNA; MS, mass spectrometry; NLS,
nuclear localization signal; PBS, phosphate-buffered saline; qRT-PCR,
quantitative reverse-transcription polymerase chain reaction; SASH1,
sterile a motif– and Src-homology 3–domain containing 1; SH2, Src-
homology 2 domain; SH3, Src-homology 3 domain; SH3N, N-terminal
Src-homology 3 domain; TGF, transforming growth factor; TNF, tumor
necrosis factor; ZEB, zinc-ﬁnger dEF1 family.
Most current article
© 2019 The Authors. Published by Elsevier Inc. on behalf of the AGA
Institute. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
2352-345X
https://doi.org/10.1016/j.jcmgh.2018.08.007Mmetastasis from epithelial-derived carcinomas,
while local, undisseminated tumors only rarely are lethal.1
Therefore, it is of major clinical importance to understand
the molecular mechanisms that regulate the metastatic
cascade. The transdifferentiation process referred to as
epithelial-mesenchymal transition (EMT) is believed to be
crucial for the formation of metastases because it converts
sessile epithelial cells into motile and invasive
mesenchymal-like cells. EMT is physiologically required for
embryonic development and wound healing, but can be
hijacked by cancer cells (reviewed by Kalluri and Weinberg2
and Lamouille et al3). During EMT, key epithelial charac-
teristics are suppressed, notably the epithelial adherens
junction protein E-cadherin. Thus, intercellular adhesions
are weakened or completely lost, promoting cell individu-
alization.3 In addition, typical mesenchymal properties are
induced, increasing cell survival, motility, and invasiveness.
These processes are mediated primarily by master tran-
scription factors such as the 2-handed zinc-ﬁnger dEF1
family (ZEB1/2) factors.3–6 Because cells that underwent
EMT have gained an invasive behavior, they are believed to
drive metastasis by penetrating tissue adjacent to the pri-
mary tumor. These cells then can enter the blood and lymph
system, disseminate systemically, and may ﬁnally settle
down at distant sites to spawn metastases.2 The scaffold
protein sterile a motif– and Src-homology 3 (SH3)-domain
containing 1 (SASH1) is a candidate tumor suppressor with
clinical relevance in breast and colon cancer, as well as in
other solid cancer entities.7–13 In addition, SASH1 is
involved in atherosclerosis, innate immune responses, and
skin pigmentation defects.14–18 Our group previously
showed that down-regulation of SASH1 speciﬁcally corre-
lates with poor prognosis and formation of metachronous
distant metastases in patients with colorectal cancer.8,9
Although these data conﬁrm a clinical implication of
reduced or absent intratumoral SASH1 expression, it is still
unknown how its loss or decrease mechanistically aggra-
vates tumor progression and induces formation of distantmetastases. Considering that SASH1 is thought to be a
multitissue tumor suppressor, better understanding of this
process could provide a basis for therapeutic strategies in a
wide variety of cancer entities.
Results
Loss of SASH1 Induces Epithelial-Mesenchymal
Transition
We sought to identify the mechanistic role of SASH1 in
cancer progression and metastasis formation. Because
SASH1 frequently is lost or down-regulated in colorectal
cancer,7,8 its deﬁciency was induced by CRISPR/Cas9-
editing in human HCT116 colon cancer cells. Clones were
derived from 2 independent guide RNAs to minimize the
risk of confounding off-target effects. Deﬁciency of SASH1
was conﬁrmed by immunoblot analysis and next-generation
sequencing of the genomic target area, revealing single base
pair insertions in the coding sequence of exon 1 (clone S1)
or exon 2 (clone S2), respectively, leading to premature stop
codons and absent protein expression (Figure 1A and B).
Proliferation was essentially unaffected by loss of SASH1
(data not shown), however, cellular morphology was altered
remarkably. Because a ﬁbroblast-like morphology is indic-
ative of EMT, expression of EMT-speciﬁc markers was
investigated, using treatment with the cytokine tumor ne-
crosis factor (TNF), which is known to induce EMT in
HCT116 cells, as positive control for EMT19 (Figure 1B). The
epithelial marker E-cadherin was down-regulated signiﬁ-
cantly upon SASH1 deﬁciency, while the mesenchymal
marker vimentin and the EMT-promoting transcription
factor ZEB1 were up-regulated. Compared with SASH1-
deﬁcient cells, TNF-treated parental cells showed a minor
reduction of E-cadherin and no increase in ZEB1 or vimentin
levels. Interestingly, SASH1 also was reduced upon TNF
treatment. In accordance with these results, EMT marker
expression was altered signiﬁcantly at the messenger RNA
(mRNA) level (Figure 1C). Whereas parental cells (wild
type) formed dense epithelial islets, SASH1-deﬁcient cells
(S1 and S2) acquired a ﬁbroblast-like morphology with
concomitant cell individualization (Figure 1D). In accor-
dance, immunoﬂuorescence microscopy showed barely
detectable E-cadherin staining of SASH1-deﬁcient cells,
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parental cells with primarily cortical distribution of F-actin
(Figure 1D). Loss of SASH1 induced the formation of actin
stress ﬁbers and a ﬁbroblast morphology (Figure 1D). This
observation also was reﬂected by a signiﬁcant increase in
cell size and length-to-width ratio (Figure 1E). As a com-
plementary approach, stable short hairpin RNA–mediated
depletion of SASH1 was performed. SASH1 down-
regulation led to reduced E-cadherin levels, while ZEB1
was increased (Figure 1F). E-cadherin was absent from
cell–cell interfaces, and cells also acquired a ﬁbroblast-like
morphology (Figure 1F). Therefore, both down-regulation
and loss of SASH1 induced EMT in HCT116 cells.SASH1 Is a Negative Regulator of
EMT-Associated Aggressiveness
To verify whether loss of SASH1 induces a bona ﬁde EMT
that generates aggressive cancer cells, its impact was func-
tionally analyzed by migration and invasion assays. SASH1-
deﬁcient clones showed a highly signiﬁcant increase in
transmigrated and Matrigel (Sigma Aldrich, Steinheim,
Germany)-invading cells (Figure 2A). Furthermore, cells
were cultured in Matrigel to analyze colony morphology in a
3-dimensional matrix. Parental cells formed rounded col-
onies with a smooth surface (Figure 2B, arrowheads).
Consistent with the EMT-like phenotype in 2-dimensional
cultures, SASH1-deﬁcient cells formed morphologically
differing cell clusters, as single cells disseminated from the
colony and invaded the extracellular matrix (Figure 2B, ar-
rows). Next, soft agar assays were used to probe anchorage-
independent growth and survival. The number and size of
colonies were increased signiﬁcantly upon loss of SASH1
(Figure 2C). Thus, SASH1 deﬁciency induces a bona ﬁde
EMT with increased migration and invasion, and increased
survival in soft agar. Based on our observation of reduced
SASH1 levels upon TNF treatment, we focused on the hith-
erto unknown transcriptional regulation of SASH1. TNF
indeed induced EMT within 48 hours, as judged by loss of E-
cadherin–mediated intercellular adhesions and ﬁbroblast-
like morphology (Figure 2D). HEK293 cells were trans-
fected with luciferase reporters under the control of various
fragments of the putative regulatory region of the SASH1
gene (Figure 2E, upper panel). Of note, a robust and sig-
niﬁcant constitutive reporter activity was detected for a 1-
kb region immediately upstream of the transcription start
(Figure 2E, lower left panel). HCT116 cells were transfected
with the 1-kb reporter construct, and stimulation with TNFFigure 1. (See previous page). CRISPR/Cas9-mediated SAS
type. (A) Domain architecture of SASH1, and premature stop
generated by independent guide RNAs. (B) Immunoblot analys
HCT116 cells. As control, parental cells were treated with 20 ng/m
of E-cadherin levels (Mann–Whitney test; n¼ 4 independent expe
to determine expression of CDH1, ZEB1, ZEB2, and VIM (Mann–
Immunoﬂuorescence staining (40 objective; scale bar: 20 mm
phenylindole for nuclei (blue). (E) Quantiﬁcation of cell size (unpa
(unpaired t test; n ¼ 20 cells; P < .0001). (F) Immunoblot and im
stably transfected with vector control (Ctrl) or short hairpin RN
(kilodalton); Pro-rich, Proline-rich region; Rel, relative; SAM, stericaused a signiﬁcant decrease of SASH1 reporter activity,
while controls showed no alterations (Figure 2E, lower right
panel). In accordance, expression of both CDH1 and SASH1
were reduced at the mRNA level (Figure 2F). Importantly,
SASH1 expression also was down-regulated in cancer cell
lines derived from further entities, including SW480 (colo-
rectal cancer), PANC-1 (pancreatic ductal adenocarcinoma),
Huh7 (hepatocellular carcinoma), and H1650 (non–small-
cell lung cancer) after treatment with transforming growth
factor (TGF)-b1 for 48 hours, indicating a general role of
SASH1 in EMT, independent from the inducing agent and
cancer entity (Figure 2F).SASH1 Interacts With the Oncoprotein and
Signal Adaptor V-Crk Avian Sarcoma Virus
CT10 Oncogene Homolog-Like
To determine if forced expression of SASH1 can coun-
teract TNF-induced EMT, SASH1 with a C-terminal V5-
epitope tag was expressed transiently in parental HCT116.
In contrast to control transfected cells, TNF treatment
induced only a minor reduction of E-cadherin levels in
SASH1-V5–expressing cells. Of note, overexpression of
SASH1 was associated with apoptosis, as indicated by
Poly(ADP-Ribose)-Polymerase 1 cleavage and reduced
SASH1-V5 levels (Figure 3A). The epithelial state of SASH1-
V5–expressing cells after TNF administration was high-
lighted further by a cobblestone-like morphology and
E-cadherin strongly localizing to intercellular adhesions
(Figure 3B). Next, to investigate the molecular mechanism of
the negative regulatory role of SASH1 in EMT, a yeast
2-hybrid screen was performed in a human placental
complementary DNA (cDNA) bank with SASH1 as bait.
Complementary to the yeast 2-hybrid screen, co-
immunoprecipitations were performed with SASH1 with
an N-terminal green ﬂuorescent protein (GFP) tag expressed
in HEK293 cells, and analyzed by mass spectrometry, using
GFP-only transfected cells as control. As potential binding
partners, the yeast 2-hybrid screen showed 28 protein
coding hits (Figure 3C). Among these candidates, the V-Crk
avian sarcoma virus CT10 oncogene homolog family of
adaptor proteins (the V-Crk avian sarcoma virus CT10
oncogene homolog [CRK] and V-Crk avian sarcoma virus
CT10 oncogene homolog-like [CRKL]) were published to be
EMT-related. However, only CRKL was detected indepen-
dently by co-immunoprecipitation. For these reasons, we
focused on CRKL as a potential EMT-related interaction
partner of SASH1. First, the putative interaction betweenH1 deﬁciency in HCT116 induces a mesenchymal pheno-
codons of SASH1-deﬁcient clones (S1*, S2*), which were
is of SASH1-deﬁcient (S1, S2) and parental (wild-type [WT])
L TNF for 48 hours to induce EMT. Immunoblot quantiﬁcation
riments; P¼ .0286) is also shown. (C) qRT-PCR was performed
Whitney test; n ¼ 4–6 independent experiments; P  .019). (D)
) for E-cadherin (green), F-actin (red), and 40,6-diamidino-2-
ired t test; n ¼ 40 cells; P < .0001) and length-to-width ratio
munoﬂuorescence microscopic analysis of parental HCT116
A (shRNA) vector targeting SASH1. Mr (K), molecular range
le a motif. *P  .05; **P  .01; P  .001; ****P  .0001.
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endogenous proteins (Figure 3D). Furthermore, SASH1 with
a V5-epitope tag and endogenous CRKL co-localized in the
cytoplasm, and at phase-dense structures, partly identiﬁed
as focal adhesions by paxillin staining (data not shown)
(Figure 3E). Because of relatively low SASH1-V5 levels in the
nuclei, as well as increased nuclear CRKL staining in cells
lacking SASH1-V5 (Figure 3E, asterisk), the predicted nu-
clear localization signals (NLS)1 and NLS2 within SASH1
were disabled by site-directed mutagenesis, either alone
or combined, efﬁciently blocking nuclear import of the
N-terminal fragment (Figure 3F). Therefore, nuclear shut-
tling of SASH1 is mediated by both amino-terminal NLS
signals, and SASH1 likely interacts with CRKL both in
cytoplasm and nucleus.
The N-Terminal SH3 Domain of CRKL Interacts
With a PXXPXK Motif of SASH1
Next, the binding mode between SASH1 and CRKL was
mapped using full-length and truncated SASH1 constructs
with N-terminal GFP or C-terminal V5 epitopes (Figure 4A)
expressed in HEK293 cells, as described before.20 Immu-
noprecipitation showed that only constructs containing the
C-terminal part of SASH1 bind to endogenous CRKL
(Figure 4B and C). However, the NLS showed no impact on
CRKL binding (Figure 4C). CRKL is known to bind speciﬁc
PXXPXK/R motifs of its downstream effector proteins (eg,
C3G), mediated by its N-terminal SH3 domain (SH3N).21,22
Analysis of the SASH1 primary structure (Research Collab-
oratory for Structural Bioinformatics Protein Data Bank-
entry: O94885) showed 3 PXXPXK motifs within the
C-terminal part as putative CRKL binding sites (aa865-870,
984-989, and 1016-1021). Site-directed mutagenesis of
SASH1 was performed by alanine substitution of the 3
PXXPXK motifs to AXXAXK. Immunoprecipitations of
endogenous CRKL showed that only mutation of the second
PXXPXK motif (aa984-989), or of all PXXPXK motifs
together, disrupted CRKL binding (Figure 4D, left panel).
Furthermore, mutation of a tryptophan residue to arginine
(W160R) within the CRKL SH3N domain, reported to be
important for domain function,23 abolished the interaction
with C3G, as well as with SASH1 (Figure 4D, right panel). AsFigure 2. (See previous page). Loss of SASH1 activates a bo
were performed with SASH1-deﬁcient (S1, S2) and parental (w
pendent experiments; P ¼ .0022). (B) In contrast to parental cel
cells grown in a 3-dimensional Matrigel culture for 5 days freque
as single cells (arrows; scale bar: 50 mm). (C) Cells were grown in
t test; n ¼ 9 independent experiments; P < .0001) and colony s
.0001) was assessed. (D) Parental cells treated with 20 ng/mL
immunoﬂuorescence microscopy (40 objective, scale bar: 20 m
phenylindole (DAPI) for nuclei (blue). (E) Shown is the proximal
structs. Luciferase assays were performed to compare the ac
pGL3-basic vector, as well as the SV40 promoter containing
panel; Mann–Whitney test; n  3 independent experiments; P ¼
formed with HCT116 cells treated with 20 ng/mL TNF for 24 ho
.0286). (F) SASH1 and CDH1 expression levels after induction o
4–6 independent experiments; P  .019), as determined by q
cadherin levels upon treatment of a panel of cell lines with 20 n
Huh7, H1650) for 48 hours. Ctrl, control; Rel, relative; RoI, regioa control, the CRKL interaction partner GAB1,24 which binds
to the Src-homology 2 (SH2) domain of CRKL, still interacted
with CRKLW160R. Thus, the interaction between SASH1 and
CRKL is mediated by the CRKL SH3N domain, binding the
second PXXPXK motif of SASH1. Importantly, recombinant
expression of SASH1 signiﬁcantly inhibited CRKL binding to
its effector C3G, while the interaction with GAB1 remained
unaffected (Figure 4E). The apparent afﬁnity between a
peptide corresponding to the second PXXPXK motif of
SASH1 (QPPPVPAKKS) and the recombinant CRKL SH3N
domain was determined by a dynamic mass redistribution-
based assay (dissociation constant ¼ 7.4 ± 1.637 mmol/L)
(Figure 4F).
SASH1 Negatively Regulates EMT
Through CRKL
As a working hypothesis, SASH1 physically associates
with CRKL and counteracts its EMT-promoting signaling.
CRKL deﬁciency thus was induced in parental and SASH1-
deﬁcient cells, using 2 independent guide RNAs (clones C1
and C2 in parental cells). CRKL deﬁciency induced a more
pronounced epithelial morphology with densely packed,
cobblestone-like islets (Figure 5A). Strikingly, loss of CRKL
in SASH1-deﬁcient cells (S1C2) completely reverted their
ﬁbroblast-like morphology into a clear epithelial phenotype
(Figure 5A). Essentially the same phenotype was observed
for an independent SASH1/CRKL-deﬁcient clone (S2C2, data
not shown). Loss of CRKL in SASH1-deﬁcient cells restored the
expression of EMT markers to the parental levels (Figure 5B).
CRKL deﬁciency did not affect anchorage-independent growth
in parental cells, but highly signiﬁcantly reduced colony
number and size of SASH1-deﬁcient cells (Figure 5C).
Furthermore, increased migration and invasion of SASH1-
deﬁcient cells was completely reverted by loss of CRKL
(Figure 5D). Thus, EMT induced by loss of SASH1 completely
depends on the presence of its interaction partner CRKL.
EMT Induced by Loss of SASH1 Depends on
CRKL-Mediated SRC Signaling
CRKL was reported to play unique roles in integrin
signaling at focal adhesions.25–27 To investigate if SASH1
negatively regulates EMT through these signaling pathwaysna ﬁde EMT program in HCT116 cells. (A) Transwell assays
ild-type [WT]) HCT116 cells (Mann–Whitney test; n ¼ 6 inde-
ls, which form dense colonies (arrowheads), SASH1-deﬁcient
ntly detach from the colony and invade the extracellular matrix
soft agar for 14 days, before the number of colonies (unpaired
ize (unpaired t test; n ¼ 24 colonies; S1: P ¼ .0007; S2: P <
TNF for 48 hours undergo EMT, as judged by staining for
m) for E-cadherin (green), F-actin (red), and 40,6-diamidino-2-
promoter of SASH1 and corresponding pGL3 reporter con-
tivity of SASH1 promoter sequences with the promoter-less
positive pGL3-control plasmid in HEK293 cells (lower left
.0286). Luciferase assays (lower right panel) also were per-
urs (Mann–Whitney test; n ¼ 4 independent experiments; P ¼
f EMT by 20 ng/mL TNF for 48 hours (Mann–Whitney test; n ¼
RT-PCR (left panel). Immunoblot analysis of SASH1 and E-
g/mL TNF (HCT116), or 10 ng/mL TGF-b1 (SW480, PANC-1,
n of interest.
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ﬁbronectin-coated plates. SASH1-deﬁcient cells showed
signiﬁcantly increased tyrosine-phosphorylation levels of
SRC family kinases at the activating residue Y416, as well as
of paxillin at Y118, which was abolished by loss of CRKL
(Figure 6A and B). SASH1-deﬁcient cells formed focal
adhesions after 3 hours of adhesion, while parental or
CRKL-deﬁcient cells poorly spread and rarely formed
phospho-paxillin–positive foci (Figure 6C). After 24 hours,
SASH1-deﬁcient cells showed multipolar lamellipodia with
abundant phospho-paxillin–positive focal adhesions, while
parental cells showed few adhesive structures (Figure 6D).
CRKL deﬁciency strongly reduced the development of focal
adhesions in parental and SASH1-deﬁcient cells.
Next, CRKL was recombinantly expressed in parental
HCT116, which led to tyrosine phosphorylation of SRC and
paxillin, phenocopying a loss of SASH1. This effect was
inhibited by the Abl/SRC-inhibitor dasatinib (Figure 6E).
Importantly, pharmacologic inhibition of SRC via dasatinib
counteracted the mesenchymal phenotype of SASH1-
deﬁcient cells (S1 and S2), as E-cadherin was increased to
the levels of compound SASH1/CRKL-deﬁcient cells (S1C2
and S2C2) (Figure 6F). ZEB1 was slightly decreased (S1) or
undetectable (S2) after treatment with dasatinib. Thus, EMT
induced by loss of SASH1 directly depends on CRKL-
dependent SRC signaling.SASH1 Inhibits Metastasis Formation In Vivo in a
CRKL-Dependent Manner
An orthotopic xenograft model was applied to analyze
the metastatic capability of SASH1-deﬁcient (S1), compound
SASH1/CRKL-deﬁcient (S1C2), and parental (wild-type)
HCT116 cells. Cells were retrovirally transduced to express
luciferase and injected in immune-deﬁcient mice into the tip
of the cecum, previously enclosed by absorbable surgical
suture. This model allowed tumors to form upon local in-
vasion of the cecum mucosa at the site of implantation. After
34 days, animals were killed and analyzed byFigure 3. (See previous page). Identiﬁcation of the signal
SASH1. (A) Immunoblot analysis of parental HCT116 cells tran
SASH1 with a C-terminal V5 tag. Cells were stimulated with
quantiﬁcations also are shown (unpaired t test; n ¼ 3 indepen
croscopy (scale bar: 20 mm) of control or SASH1-V5–transfected
hours. Fixed cells were stained with an anti-V5 antibody (re
phenylindole for nuclei (DAPI; blue). (C) To screen for potential
performed with SASH1 as bait protein and a human placental
conﬁdence (signiﬁcance A–C), and the corresponding number
PubMed database. In addition, SASH1 with an N-terminal GFP t
to analyze co-precipitating proteins via mass spectrometry. Yeas
co-precipitation/mass spectrometry are indicated. (D) Endogeno
HEK293 cell lysates, while the isotype control antibody shows no
C-terminal V5 epitope were stained for immunoﬂuorescence m
antibody. SASH1-V5 and CRKL showed a pronounced co-loc
the cell (arrowheads). (F) Immunoﬂuorescence microscopy (sca
constructs with wild-type (WT) or mutated (mut) nuclear locali
antibody (red) and DAPI for nuclei (blue). COIP, co-immunop
Mr (K), molecular range (kilodalton); PARP, Poly(ADP-Ribose)-Pbioluminescence imaging (Figure 7A). Mice harbored
palpable primary tumors, histologically conﬁrmed as poorly
differentiated colon carcinoma with similar overall tissue
architecture for all 3 cell lines (Figure 7A). Importantly,
tumors derived from SASH1-deﬁcient cells featured a
strongly reduced E-cadherin staining, in accordance with
our in vitro ﬁndings (Figure 7A).
To quantitatively assess the metastatic capability,
bioluminescence was measured post-mortem before and
after resection of primary tumors. Automated quantiﬁcation
after removal of the primary tumor showed a signiﬁcant
increase in the total number of metastatic lesions generated
by SASH1-deﬁcient cells compared with parental cells
(Figure 7B, left panel). This increase was fully blocked by
CRKL deﬁciency as compound SASH1/CRKL-deﬁcient cells
were essentially identical to the parental line. To quantify
the relative distribution of tumor cells, the signal ratio of
distant lesions after removal of the primary tumor was
calculated relative to the total signal before removal of the
primary tumor (Figure 7B, right panel). In contrast to
parental and compound SASH1/CRKL-deﬁcient lines,
SASH1-deﬁcient cells showed a signiﬁcantly higher relative
metastatic luminescence signal. Thus, although a similar
tumor burden was induced by the different cell lines, a
drastic difference was apparent in tumor dissemination.
Parental and compound SASH1/CRKL-deﬁcient cells
showed locoregional spread, while SASH1-deﬁcient cells
showed massive distant dissemination.
Tissue sections were analyzed with an antibody
speciﬁcally staining human cells.28 Peritoneal carcino-
matosis occurred in essentially all mice injected with
parental or compound SASH1/CRKL-deﬁcient cells as
lesions were attached to the outer surface of host organs
within the peritoneum (Figure 7C, left panels). In
contrast, secondary lesions from SASH1-deﬁcient cells
were completely enclosed by host tissue, and tumor cells
often were dispersed extensively as small clusters or
single cells (Figure 7C, right panels). In addition, only
SASH1-deﬁcient cells were detected within intrahepaticadaptor CRKL as an EMT-related interaction partner of
siently transfected with control vector or a vector to express
20 ng/mL TNF or vehicle control for 48 hours. Immunoblot
dent experiments; P ¼ .0094). (B) Immunoﬂuorescence mi-
cells, either untreated or stimulated with 20 ng/mL TNF for 48
d), anti–E-cadherin antibody (green), and 40,6-diamidino-2-
interaction partners of SASH1, a yeast 2-hybrid screen was
cDNA bank. Shown are protein coding hits of good and high
of articles from “<gene name> and EMT” searches in the
ag was transiently expressed in HEK293 cells and precipitated
t 2-hybrid hits that also were found to interact with SASH1 via
us CRKL co-precipitates endogenous SASH1 in HCT116 and
signal. (E) HEK293 cells transiently expressing SASH1 with a
icroscopy (scale bar: 10 mm) with an anti-V5 and anti-CRKL
alization at phase-dense structures in peripheral regions of
le bar: 20 mm) of HeLa cells expressing SASH1-V5 deletion
zation signals. Cells were ﬁxed and stained with an anti-V5
recipitation; IP, immunoprecipitation; ISO, isotype antibody;
olymerase 1; SIGN, signiﬁcance.
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were capable of hematogenic and lymphogenic systemic
dissemination, as evidenced by detection of human cancercells in lungs of the host (Figure 7C, lower right panel).
Human E-cadherin was strongly expressed in distant
lesions from parental cells, whereas SASH1-deﬁcient
42 Franke et al Cellular and Molecular Gastroenterology and Hepatology Vol. 7, No. 1secondary lesions showed only low staining (Figure 7C,
lower panels).
To address the question of whether SASH1 and CRKL
play a clinical role and are involved in survival of patients
with colorectal cancer, genetic alterations and aberrant
expression of both genes were assessed in the publicly
available TCGA data set consisting of 233 colorectal cancer
patients, with full sequence information and available
follow-up data in the cBioPortal (Memorial Sloan Kettering
Cancer Center, New York, NY) platform.29,30 SASH1 was
down-regulated or homodeleted, and CRKL was increased
or genomically ampliﬁed in 10.8% of cases (23 of 213).
There was a trend toward mutual exclusivity of both alter-
ations in individual patients. Kaplan–Meier analysis showed
a signiﬁcantly reduced overall survival in the subgroup with
up-regulated CRKL and/or down-regulated SASH1
(Figure 7D). Therefore, SASH1 and its interaction partner
CRKL have prognostic signiﬁcance in colorectal cancer. In
addition, SASH1 and CRKL expression was analyzed in an
independent patient cohort with locally advanced colorectal
cancer (Union for International Cancer Control/American
Joint Committee on Cancer stage III, n ¼ 76) by quantitative
reverse-transcription polymerase chain reaction (qRT-PCR)
(Figure 7E). In accordance with earlier ﬁndings, SASH1
expression was highly signiﬁcantly down-regulated in tu-
mor tissue (Figure 7E, upper right panel), whereas expres-
sion of CRKL was increased signiﬁcantly compared with
normal colon tissue (Figure 7E, lower right panel). Because
of the relevance of EMT in chemoresistance,31,32 the resis-
tance to 5-ﬂuorouracil was probed in vitro (Figure 7F, upper
panel). SASH1-deﬁcient cells showed an increased resis-
tance to 5-ﬂuorouracil, which was dependent on the pres-
ence of CRKL, because loss of CRKL either in SASH1-deﬁcient
(Figure 7F, upper panel) or parental cells (not shown)
signiﬁcantly increased the cytotoxic effects. In accordance,
survival of stage III colorectal cancer patients receiving
5-ﬂuorouracil as an adjuvant chemotherapeutic agent was
reduced signiﬁcantly in the subgroup with high intratumoral
CRKL expression (Figure 7F, lower panel). Intratumoral
SASH1 expression was not correlated signiﬁcantly with
response to 5-ﬂuorouracil therapy (data not shown).Figure 4. (See previous page). The N-terminal SH3 domain
(A) Shown are several SASH1 deletion constructs tagged with a
to map the CRKL binding site. Length of SASH1 constructs a
(B) Endogenous CRKL was precipitated with an anti-CRKL an
deletion constructs with N-terminal GFP tags. Full-length GFP
C-terminal part of SASH1 (aa1–887 and 709–1247) co-precipi
performed with SASH1 constructs carrying a C-terminal V5-ep
tation with anti-V5 and anti-CRKL antibodies showed that e
(aa590–1247). (D) SASH1 contains 3 distinct PXXPXK motifs (P1
motif (P2, aa984–989) of GFP-SASH1 is sufﬁcient to disrupt c
immunoprecipitations show that the interaction of CRKL (fuse
GAB1, is abolished by the W160R mutation that inactivates the N
expression of SASH1 with a C-terminal V5 tag in HEK293 ce
(unpaired t test; n ¼ 3 independent experiments; P ¼ .0310), wh
between SASH1 and CRKL was determined by dynamic mass re
second PXXPXK motif of SASH1 (aa982–991) and the N-termi
CRKL with an apparent dissociation constant of dissociation
immunoprecipitation; Mr (K), molecular range (kilodalton); P1–3,
red ﬂuorescent protein; SAM, sterile a motif; WB, Western blotDiscussion
Metastases account for the majority of cancer-related
deaths,1 in the case of colorectal cancer most frequently
spreading to the liver or lungs. Thus, it is of huge clinical
importance to understand metastasis formation and to ﬁnd
druggable targets. The differentiation process of EMT turns
epithelial cells into highly invasive mesenchymal-like cells,
proposed as an essential prerequisite for the formation of
metastases.2,3,33 The present study shows that loss or down-
regulation of the tumor-suppressor SASH1 is sufﬁcient to
induce EMT. Furthermore, cytokine-induced EMT resulted
in a strong reduction of SASH1 expression in a panel of
carcinoma cell lines. Forced expression of SASH1 in turn
counteracted EMT induced by TNF. Therefore, multiple lines
of evidence have indicated a reciprocal relation between
EMT and SASH1, and established SASH1 as a key negative
regulator of EMT. In support, EMT induced by hypoxia or
TGF-b1 was shown independently to down-regulate SASH1
in a pancreatic and gastric cell line, respectively.34,35 Down-
regulation of SASH1 expression during EMT thus fosters the
conversion toward a mesenchymal phenotype, representing
a feed-forward loop.
Tumor cells acquire an invasive phenotype during EMT,
enabling them to detach from the primary tumor and invade
adjacent tissue, ultimately spawning metastases.2 Loss of
SASH1 was sufﬁcient to induce a drastic increase in
migration and invasion, even in the absence of cytokines.
These data are in accordance with our previous data
because forced expression of SASH1 reduced cell migration
and increased cell-matrix adhesion,20 as well as with our
clinical results showing a signiﬁcant association between
distant metastasis and reduced SASH1 expression in colon
cancer.9 Indeed, orthotopic xenograft models showed a
signiﬁcant increase of metastatic lesions upon loss of SASH1.
This report conﬁrms that SASH1 is a tumor suppressor
in vivo, counteracting metastasis. Our data also support the
relevance of EMT during the metastatic process, which
currently is discussed controversially.31,32,36,37 Further-
more, the mechanistic involvement of SASH1 in these
processes could be clariﬁed because the phenotype ofof CRKL binds to a speciﬁc PXXPXK motif of SASH1.
n N-terminal GFP- or C-terminal V5-epitope, which were used
s well as the CRKL domain architecture also are indicated.
tibody in HEK293 cells expressing GFP or different SASH1
-SASH1 (aa1–1247) and deletion constructs containing the
tated with CRKL. (C) Reciprocal immunoprecipitations were
itope tag. In accordance to GFP-SASH1 constructs, precipi-
ndogenous CRKL binds to the C-terminal part of SASH1
–3) in the C-terminal region. Mutation of the second PXXPXK
o-precipitation with endogenous CRKL (left panel). Anti-RFP
d to RFP at the C-terminus) with C3G and SASH1, but not
-terminal SH3 domain of CRKL (right panel). (E) Recombinant
lls abrogates co-precipitation of C3G by endogenous CRKL
ile the interaction with GAB1 is not disturbed. (F) The afﬁnity
distribution (DMR) experiments using a peptide containing the
nal SH3 domain of CRKL puriﬁed from E coli. SASH1 binds
constant (±SD) of 7.378 ± 1.637 mmol/L. Ctrl, control; IP,
PXXPXK motifs; Pro-rich, proline-rich region; rel, relative; RFP,
.
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we introduce as a novel interaction partner of SASH1.
CRKL and CRK were identiﬁed as putative new interac-
tion partners of SASH1 by yeast 2-hybrid screening.
Although both proteins are involved in EMT,38–43 only CRKL
was conﬁrmed independently by co-immunoprecipitation.
This can be explained by domain organization differences
between CRK and CRKL since the N-terminal SH3 domain of
CRK is regulated negatively by phosphorylation. CRK
therefore might not be absolutely excluded as an interaction
partner.44 CRKL is a SH2- and SH3-domain-containing
oncogenic adaptor protein involved in signaling pathways
downstream of receptor tyrosine kinases and integ-
rins.21,24,25,39,45 It binds phosphorylated, membrane-
associated proteins (eg, GAB1) via its SH2 domain.24,27
Thereby, CRKL recruits PXXPX(K/R)-motif containing ef-
fectors such as C3G through the SH3N domain to the
membrane, leading to activation of small guanosine tri-
phosphatases (GTPases), and thus inducing downstream
signaling.21,24,45 Our data indicate that SASH1 binds to the
SH3N domain of CRKL primarily through a PXXPXK motif
(aa984–989) with an afﬁnity in the low micromolar range.
The interaction may be supported through other PXXPXK
motifs of SASH1 because a deletion construct containing
another motif (aa1–887) also co-precipitated with CRKL.
Importantly, SASH1 inhibited interactions between CRKL
and its effector protein C3G, elucidating a potential inhibi-
tory mode of action for SASH1: by tightly binding the SH3N
domain of CRKL, SASH1 abolishes interactions between
CRKL, C3G, and further effector proteins, which are essential
for CRKL signaling.21 In the absence of SASH1, C3G, and
other factors thus can act as a guanine nucleotide
exchange factor for small GTPases to induce cell migration.
Because CRKL is well established to promote EMT,39,41,42 we
assume that SASH1 inhibits EMT directly through the
competitive inhibition of CRKL downstream signaling (eg, by
preventing activation of small GTPases required for cyto-
skeletal rearrangement and efﬁcient cell migration, see the
graphic abstract). A recent study on lung carcinoma suggested
that knockdown of CRKL affects migration and invasion, but
not EMT-marker expression in mesenchymal-like carcinoma
cells.25 In the present study, however, loss of CRKL in SASH1-
deﬁcient cells not only rescued the aggressive phenotype, but
also reverted the expression of EMT markers. Furthermore,
genetic deletion of CRKL in SASH1-deﬁcient cells signiﬁcantly
decreased their aggressive prometastatic phenotype toward
the parental state in vivo. Therefore, EMT induced by SASH1
deﬁciency clearly depends on CRKL-mediated signaling. CRKL
is involved in signaling downstream of integrins at focalFigure 5. (See previous page). Loss of CRKL rescues the EMT
[WT]), SASH1-deﬁcient (S1), CRKL-deﬁcient (C1, C2), and co
subjected to immunoﬂuorescence staining (40 objective, sca
diamidino-2-phenylindole for nuclei (blue). (B) Immunoblot an
speciﬁc antibodies. (C) Cells were grown for 14 days in soft a
n ¼ 9 independent experiments; P < .0001) and colony size (unp
to quantify migration and invasion (Mann–Whitney test; n ¼
antibody; Mr (K), molecular range (kilodalton); pAb, polyclonal an
****P  .0001.adhesions, which potentially could promote EMT.22,25,27 Focal
adhesions also are important players during metastasis.46
Here, we establish SASH1 as a negative regulator of CRKL-
mediated activation of SRC family kinases. In accordance,
pharmacologic inhibition of SRC in SASH1-deﬁcient cells
phenocopied loss of CRKL, indicating that SRC activation upon
loss of SASH1 is required for the EMT phenotype. CRK has
been shown to activate SRC by association with its negative
regulatory kinase C-terminal SRC kinase,47,48 which also may
apply to CRKL. In the absence of SASH1, SRC signaling also
could be activated directly by binding of effector proteins
(eg, C3G in this study) to the CRKL SH3N domain, leading to
activation of small GTPases.
According to our working model, loss of SASH1 induces
EMT and formation of metastases owing to a lack of CRKL
inhibition. Our in vitro and in vivo ﬁndings are supported by
data obtained from clinical samples that show a striking
decrease of SASH1 and an increase of CRKL expression in
colorectal cancer compared with normal colon mucosa.
Moreover, analysis of the TCGA data set on an independent
patient cohort showed that genetic loss of SASH1, and/or
ampliﬁcation of the CRKL gene locus, occur in approxi-
mately 11% of patients, and are associated signiﬁcantly with
worse overall survival. This is in good accordance with our
earlier ﬁndings on SASH1 as a positive prognostic factor in
colorectal cancer.8,9
Importantly, chemoresistance, which has been linked to
EMT,31,32 was increased signiﬁcantly in SASH1-deﬁcient
cells, whereas loss of CRKL reverted this phenotype. The
decreased resistance in vitro against the cytotoxic com-
pound 5-ﬂuorouracil upon loss of CRKL was in accordance
with clinical ﬁndings. Patients with stage III colorectal
cancer who received adjuvant 5-ﬂuorouracil therapy had
signiﬁcantly worse survival when intratumoral CRKL
expression was increased. These ﬁndings highlight CRKL as
a promising therapeutic target. In contrast, intratumoral
SASH1 expression was not associated signiﬁcantly with
prognosis in 5-ﬂuorouracil–treated patients. Even though
decreased SASH1 expression has been reported as a nega-
tive prognostic factor,7–13 it recently was shown that
increased SASH1 expression is associated with a reduced
response to adjuvant therapy in a subgroup of breast cancer
patients.13 Therefore, independent patient cohorts are
required to make conclusive statements about the clinical
implications of our ﬁndings. However, it is tempting to
speculate that patients might be stratiﬁed by expression of
SASH1 and CRKL to identify subgroups that beneﬁt from
pharmacologic inhibition of SRC kinases, which remarkably
reduced the malignant properties of cancer cells in ourphenotype of SASH1-deﬁcient cells. (A) Parental (wild-type
mpound SASH1/CRKL-deﬁcient (S1C2) HCT116 cells were
le bar: 20 mm) for E-cadherin (green), F-actin (red), and 40,6-
alysis of EMT markers and CRKL, using 2 different CRKL-
gar before quantiﬁcation of colony number (unpaired t test;
aired t test; n ¼ 24 colonies; P < .0001). (D) Transwell assays
6 independent experiments; P ¼ .0022). mAb, monoclonal
tibody; RoI, region of interest. *P  .05; **P  .01; P  0.001;
Figure 6. SASH1 inhibits CRKL-mediated SRC signaling, which is required for the mesenchymal phenotype. (A) SASH1-
and/or CRKL-deﬁcient cells that adhered to ﬁbronectin-coated plates for 3 hours (left panel) or for 24 hours (right panel) were
subjected to immunoblot analysis. (B) Immunoblot quantiﬁcation of SRC (Y416) and paxillin (Y118) phosphorylation after 3
hours of adhesion (Mann–Whitney test; n ¼ 4 independent experiments; P ¼ .0286). *P  .05. (C) Cells that adhered for 3 hours
to ﬁbronectin-coated plates were subjected to immunoﬂuorescence staining (100 objective, scale bar: 10 mm) for Y118
phospho-paxillin (green), F-actin (red), and 40,6-diamidino-2-phenylindole for nuclei (blue). (D) The same analysis was per-
formed after 24-hour adhesion to ﬁbronectin-coated plates. (E) Immunoblot analysis of parental HCT116 cells recombinantly
expressing RFP as control or CRKL with a C-terminal RFP tag. In addition, CRKL-RFP–expressing cells were treated with 100
nmol/L dasatinib for 24 hours. (F) Parental (wild-type [WT]), CRKL-deﬁcient (C2), SASH1-deﬁcient (S1, S2), and compound
SASH1/CRKL-deﬁcient (S1C2, S2C2) cells were treated with 100 nmol/L dasatinib for 72 hours before they were subjected to
immunoblot analysis. Mr (K), molecular range (kilodalton); pPaxillin, phospho-Paxillin; pSrc, phospho-Src; RFP, red ﬂuorescent
protein.
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2019 SASH1 Blocks EMT Through Inhibition of CRKL 47analyses. Furthermore, the inhibition of CRKL, based on the
interaction with its natural inhibitor SASH1, could be a
suitable new strategy for therapeutic intervention, espe-
cially in combination with conventional chemotherapeutic
agents. Such treatments potentially could inhibit EMT-
induced tumor progression, metastasis, and chemo-
resistance, thereby preventing minimal residual disease.Patients and Methods
Cell Culture and Constructs
Human cell lines HCT116 and HEK293 (ATCC, Rockville,
MD) were cultured in Dulbecco’s modiﬁed Eagle medium
(DMEM; Invitrogen, Karlsruhe, Germany) containing 10%
fetal bovine serum (Biochrom, Berlin, Germany). HEK293
cells were transfected by precipitation with calcium phos-
phate as described earlier.20 HCT116 cells were transfected
using FuGENE HD (Promega, Madison, WI) according to the
manufacturer’s protocol. Human CRKL was cloned from
cDNA into pmRFP-N2 with primers containing KpnI and
XmaI sites. SASH1 deletion constructs were described
earlier.20 Mutagenesis of GFP–SASH1 and CRKL–RFP was
performed according to published protocols,49 using 1 pair
of primers per PXXPXK motif. For short hairpin
RNA–mediated knockdown of SASH1, pSUPER.neoþGFP
(Oligoengine, Seattle, WA), was used as described.20 The
luciferase reporter construct was generated by cloning the
proximal 1 kb of the SASH1 gene regulatory region into the
pGL3 vector. For induction of epithelial–mesenchymal
transition, cells were stimulated with 10 ng/mL TGF-b1
(Stemcell Technologies, Cologne, Germany) or 20 ng/mL
TNF (Gibco, Waltham, MA) for 48 hours in normal growth
medium. Proliferation and response to 5-ﬂuorouracil (24-
hour treatment) was probed using the Cell Proliferation
Kit II (XTT) from Roche (Mannheim, Germany). TheFigure 7. (See previous page). SASH1 suppresses metastas
deﬁcient (severe combined immunodeﬁciency/beige) mice wer
(wild-type [WT]), SASH1-deﬁcient (S1), or compound SASH1/CR
per group). Metastasis was assessed by bioluminescence ima
tumors were subjected to H&E and immunohistochemistry stai
automatically counting the number of lesions by their lumines
Mann–Whitney test; n ¼ 4–6 mice; P ¼ .019). In addition, metast
intensity before and after removal of primary tumors (right pan
sections were analyzed for the presence of tumor cells (brown
tibodies against mitochondria or E-cadherin. In parental and co
tosis frequently occurred (arrowheads), with metastatic lesion
spawned metastases enclosed by normal tissue (arrows), which
line (lower panels). (D) Genomic deletion of SASH1 and/or am
colorectal cancers (23 of 213 patients) and was associated sig
(log-rank test; n ¼ 213 patients; P ¼ .0266), based on the TCGA
University of Munich patient cohort (left panel). qRT-PCR analy
Control/American Joint Committee on Cancer stage III colorec
niﬁcant reduction of SASH1 expression (upper right panel; Ma
colon mucosa (N, n ¼ 16 patient samples). The expression of
panel; Mann–Whitney U test; P ¼ .03). (F) Chemoresistance of
CRKL-deﬁcient (S1C2) cells was analyzed by XTT (Roche)
ﬂuorouracil for 24 hours to determine the median inhibitory co
n ¼ 4 independent experiments; P ¼ .0286). Tumor-speciﬁc sur
(5-FU) was strongly reduced in the group with high intratumoral
P ¼ .018). CRC, colorectal cancer; E-cad, E-cadherin; Rel, relafollowing antibodies were used: E-cadherin (3195; CST),
b-actin (3700; CST), SASH1 (A302-265A; Bethyl, Mont-
gomery, TX), GAB1 (A303-288A; Bethyl), C3G (Bethyl A301-
965A), RFP (5F8; Chromotek, Martinsried, Germany), V5
epitope tag (MA5-15253; Thermo Scientiﬁc, Waltham, MA),
Poly(ADP-Ribose)-Polymerase 1 (ab137653; Abcam, Cam-
bridge, UK), GFP (3H9; Chromotek), CRK-II (sc-289; SCBT,
Heidelberg, Germany), CRKL (05-414; EMD Millipore,
Darmstadt, Germany), CRKL (sc-319; SCBT), ZEB1
(HPA027524; Sigma, Steinheim, Germany), vimentin
(ab92547; Abcam), Y118 phospho-paxillin (2541; CST,
Danvers, MA), paxillin (12065; CST), Y416 phospho-Src
family (6943; CST), Src (2123; CST), human mitochondria
(ab92824; Abcam), human E-cadherin (ab40772; Abcam),
RFP-trap (rta-10; Chromotek), and GFP trap (gta-10; Chro-
motek). The following primers were used: cloning of CRKL-
RFP: 50-CAAGGTACCATGTCCTCCGCCAGG-30 and 50-GCCCGG







TGGGGAG-30; CRKL W160R: 50-GAACAGCGGTGGAGTGCCCGG
AACAAGG-30 and 50-GCACTCCACCGCTGTTCTTCAGGCTTCTC-
30; ampliﬁcation of guide RNA (gRNA) target locus gRNA1:
50-CACATCCGAGGCGTTCTC-30 and 50-TGTGTGTATTTAGCCCC
CTAAG-30; gRNA2: 50-GCGCAGCAGTATGCAGATTA-30 and
50-GTGCAGCAGCCTACAGATTG-30; cloning of luciferase
reporter constructs with SASH1_1 kb forward (-972):
50-CCGGTACCGACATGCTCTTATCCCCTTTCAAG-30; SASH1_0.25
kb-30 forward (-250): 50-CCGGTACCGCATTGTAGCGACAC
GGACTACTTG-30; SASH1_0.25 kb-30 reverse (-250): 50-
GAACGCGTAAGTAGTCCGTGTCGCTACAATGC-30; SASH1_0.25is formation in a CRKL-dependent manner. (A) Immuno-
e injected orthotopically with luciferase expressing parental
KL-deﬁcient (S1C2) HCT116 cells into the cecum (n ¼ 6 mice
ging before and after removal of the primary tumor. Primary
ning for human E-cadherin. (B) Metastasis was quantiﬁed by
cence signal after removal of the primary tumor (left panel;
atic efﬁciency was assessed by the ratio of total luminescence
el; Mann–Whitney test; n ¼ 4–6 mice; P ¼ .0381). (C) Organ
staining) by immunohistochemistry with human-speciﬁc an-
mpound SASH1/CRKL-deﬁcient cells, peritoneal carcinoma-
s showing central necrosis (asterisk). SASH1-deﬁcient cells
showed low E-cadherin staining compared with the parental
pliﬁcation of CRKL expression was observed in 10.8% of
niﬁcantly with poor overall survival in Kaplan–Meier analysis
data set. (E) Clinicopathologic characteristics of the Technical
sis of the patient cohort with Union for International Cancer
tal cancer (T, n ¼ 76 patient samples) showed a highly sig-
nn–Whitney U test; P < .0001) compared with nondiseased
CRKL was increased signiﬁcantly in tumor tissue (lower right
parental (WT), SASH1-deﬁcient (S1), and compound SASH1/
assays after treatment with varying concentrations of 5-
ncentration (IC50) values (upper panel; Mann–Whitney test;
vival for stage III patients who received adjuvant 5-ﬂuorouracil
CRKL expression (lower panel; log-rank test; n ¼ 25 patients;
tive. *P  .05; **P  .01; ***P  .001; **** P  .0001.
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AGG-30; SASH1_2 kb forward (-2094): 50-CCGGTACCTT
GAAAACCCATCTGGCCTAACTC-30; SASH1_1 kb reverse (-34):
50-GGAGATCTCTCTCCCTCGAGGCTAAAGAA automatic gain
control-30.
Generation of SASH1- and/or CRKL-Deﬁcient Cells
SASH1- and CRKL-deﬁcient cells were generated with the
CRISPR/Cas9 system. The vector pSpCas9(BB)-2A-Puro
(PX459) V2.0 was a gift from Feng Zhang (plasmid 62988;
Addgene, Cambridge, MA).50 Two different guide RNAs per
gene were cloned into the PX459 vector according to pub-
lished protocols,50 with the target genes SASH1 (gRNA1:
50-CGACTCTGGACCGACGTGAT-30; gRNA2: 50-GTTTCTCCGAC
GTGTGCGAG-30) and CRKL (gRNA1: 50-GTCCGAGGAGTCG
AACCTGG-30; gRNA2: 50-CGAGGAGTCGAACCTGGCGG-30).
HCT116 cells were transfected using FuGENE HD (Promega)
according to the manufacturer’s protocol. Two days later,
cells were selected with 5 mg/mL puromycin for 72 hours.
Single colonies were isolated and analyzed for SASH1 or
CRKL protein levels by immunoblotting during several
passages to ensure a complete loss of the respective protein.
Speciﬁc primers were used for ampliﬁcation of the genomic
CRISPR/Cas9 target area. These amplicons then were
sequenced via NGS CRISPR amplicon sequencing (CCIB DNA
Core, Massachusetts General Hospital, Boston, MA).
Co-immunoprecipitation
Co-immunoprecipitation was performed as described
previously.20 Brieﬂy, cells were lysed in RIPA buffer (50
mmol/L Tris-HCl [pH 7.4], 150 mmol/L NaCl, 1% NP-40,
0.25% sodium deoxycholate, 1 mmol/L EDTA [pH 8.0],
1 mmol/L Na3VO4, 1 mmol/L NaF, 1 mmol/L Pefabloc,
2 protease inhibitor cocktail [Roche], 1 mmol/L
b-glycerophosphate, 1 mmol/L benzamidine, 1 mmol/L
phenylmethylsulfonyl ﬂuoride, 1 mg/mL Pepstatin), total
protein was quantiﬁed with the Pierce BCA Protein Quanti-
ﬁcation Kit (Thermo Fisher Scientiﬁc), and equal concentra-
tions of cleared lysates were incubated with 2 mg antibody
for 2 hours at 4C with end-over-end rotation before protein
A– or protein G–Sepharose (Sigma-Aldrich) was added. After
further rotation for 1 hour at 4C, beads were washed 4 times
with RIPA buffer. Bound proteins were eluted by addition of
Laemmli buffer and subjected to immunoblotting.
Reverse Transcription and qRT-PCR
RNA isolation and reverse transcription from cell lines
and tissue was performed with the RNeasy Kit (Qiagen,
Hilden, Germany) as described before.8,9 Gene expression at
the mRNA level was determined by qRT-PCR using the
LightCycler 480 II system (Roche) and speciﬁc primers.
Hypoxanthine-guanine phosphoribosyltransferase was used
as an internal reference transcript and a pool of human
mucosal cDNA for normalization. The following primers
were used: CDH1 (universal probe library [UPL] #84): 50-
TGGAGGAATTCTTGCTTTGC-30 and 50-CGCTCTCCTCCGAA
GAAAC-30; CRKL (UPL #77): 50-GGCCCTGCTGGAGTTTTAC-30
and 50-TTGGTGGGCTTGGATACCT-30; SASH1 (UPL #25):50-CTTGGCACAGGACTGAGGA-30 and 50-GGTCAAAGAGAACC
GCACTAA-30; VIM (UPL #39): 50-GACCAGCTAACCAACGAC
AAA-30 and 50-GAAGCATCTCCTCCTGCAAT-30; ZEB1 (UPL
#34): 50-TTTTTCCTGAGGCACCTGAA-30 and 50-TGAAAATG
CATCTGGTGTTCC-30; ZEB2 (UPL #6): 50-GCTCGCACTAC
AATGCATCA-30 and 50-GGGAAATTGATGAATAGCGAAA-30.
Immunoﬂuorescence Microscopy
Immunoﬂuorescence microscopy was performed as
described previously.20 Brieﬂy, cells were ﬁxed with 3%
paraformaldehyde in phosphate-buffered saline (PBS) for
20 minutes, permeabilized with 0.1% Triton X-100 (Carl
Roth, Karlsruhe, Germany) in PBS for 3 minutes, blocked
with 2% (wt/vol) bovine serum albumin (BSA; Sigma-
Aldrich) in PBS for 1 hour at room temperature, and incu-
bated with the appropriate primary antibody in blocking
buffer overnight at 4C. Afterward, cells were incubated
with Alexa Fluor 488– or Cy3-conjugated secondary anti-
bodies (Thermo Scientiﬁc) in blocking buffer for 1 hour at
room temperature, before they were mounted on glass
slides with Prolong Gold antifade (Life Technologies, Wal-
tham, MA). Images were acquired with a Zeiss AxioObserver
Z1 microscope (Carl Zeiss, Jena, Germany).
Transwell Migration and Invasion Assays
Transwell migration (8.0-mm Transwell Permeable Sup-
ports, 3422; Costar, Washington DC) and invasion assays
(8.0-mm Matrigel Invasion Chamber, 354480; Corning,
Corning, NY) were performed according to the manufac-
turer’s protocol. Brieﬂy, inserts were coated for 2 hours at
37C with DMEM containing 10% fetal bovine serum. For
Transwell assays, 1  105 cells were placed on the upper
layer of the insert in DMEM without supplements and
allowed to migrate toward DMEM containing 10% fetal
bovine serum for 20 hours. The same gradient was used for
the invasion assay, but with 2  105 cells in the upper
chamber and a 40-hour incubation time. Afterwards, cells
were ﬁxed with 3% paraformaldehyde in PBS for 20 mi-
nutes, permeabilized with 0.5% Triton X-100 for 10 mi-
nutes, and stained with 40,6-diamidino-2-phenylindole. Cells
at the upper layer of the insert were carefully scratched off.
Images of ﬂuorescent nuclei were acquired with a 10
objective (Zeiss AxioObserver Z1) to quantify the number of
cells per region with the image analysis software ImageJ
v1.51 (National Institutes of Health, Bethesda, MD).
Soft Agar Assay and 3-Dimensional Culture
in Matrigel
Soft agar assays for anchorage-independent growth were
performed in 12-well plates, in which a bottom layer of 0.5
mL DMEM containing 10% fetal bovine serum and 0.6%
agarose was allowed to solidify. Cells (2500 per well) were
seeded in 0.5 mL DMEM with 10% fetal bovine serum and
0.4% agarose on top of the bottom layer. After solidiﬁcation,
0.5 mL DMEM containing 10% fetal bovine serum was
added on top of the well. Cells were grown for 2 weeks with
medium being replenished every 3 days. The colony number
then was counted manually with a 5 objective and an
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addition, image acquisition of single colonies was performed
with a 20 objective in a Zeiss AxioObserver Z1. Colony size
then was determined by measuring the area using ImageJ
software v1.51 (National Institutes of Health). To culture
cells in a 3-dimensional matrix, Matrigel was diluted 1:1
with DMEM containing 10% fetal bovine serum and allowed
to solidify in a 96-well plate to generate a bottom layer. On
top of this layer, 100 cells were seeded in the same extra-
cellular matrix gel composition. Cell growth was monitored
daily and images were acquired after 7 days of incubation
(Zeiss AxioObserver Z1).
Luciferase Reporter Assay
The plasmids pGL3 control (Promega), pGL3 basic
(Promega), and pGL3 SASH1 (containing the -972 to -34 bp
upstream of the SASH1 transcription start site) were co-
transfected with the pCMVR renilla reporter plasmid
(Promega) in a ratio of 1:1. Cells were grown for 24 hours
before media was changed. After 6 hours, cells were incu-
bated with 10 ng/mL TNF (Gibco) for a further 24 hours.
Cells were washed with PBS before being lysed in dual-glow
luciferase assay lysis buffer. Enzymatic activity was eluci-
dated following the Promega dual-glow luciferase assay kit
manual, using a Fluoroskan 2300 device (Thermo Fisher).
Relative luciferase activity was calculated as the quotient of
ﬁreﬂy-to-renilla luciferase signals.
Mass Spectrometry
Precipitations were performed as described earlier
against GFP-only or GFP–SASH1 transiently expressed in
HEK293 cells. The samples were subjected to sodium dodecyl
sulfate–polyacrylamide gel electrophoresis and gels were
stained with Sypro Ruby (Thermo Scientiﬁc). Speciﬁc gel
bands were excised and submitted to reduction (10 mmol/L
dithiothreitol in 50 mmol/L ammonium bicarbonate for 30
min at 56C) and alkylation (50 mmol/L iodoacetamide in 50
mmol/L ammonium bicarbonate for 30 min, room tempera-
ture). In-gel digestion was performed using 250 ng trypsin
overnight at 37C, then tryptic peptides were concentrated in
a speed vacuum dryer and resuspended in 20 mL of 5% ACN
with 0.1% formic acid. Liquid chromatography–mass spec-
trometry(MS)/MS analyses were performed using an Ulti-
mate 3000 Rapid Separation liquid chromatographic system
coupled to an Orbitrap Fusion Tribrid mass spectrometer
(Thermo Fisher Scientiﬁc). Mass spectrometer settings were
as follows: full MS (automatic gain control target, 2E5; res-
olution, 60K; m/z range, 350–1500; maximum ion injection
time, 60 ms); MS/MS (normalized collision energy, 30% ±
5%; detector, ion trap; isolation window, 1.6 m/z; dynamic
exclusion time setting, 30 s; automatic gain control target,
2E4; maximum injection time, 100 ms). Fragmentation was
permitted for a precursor with a charge state of 2 to 7.
Protein identiﬁcation was performed using Mascot 2.2
(Matrix Science, Boston, MA) with a concatenated forward
and reverse SwissProt (Swiss Institute of Bioinformatics,
Lausanne, Switzerland) Human database (April 13, 2016,
40,422 entries) generated with DBToolKit. ProteinScape 2.1(Bruker, Billerica, MA) was used to run Mascot with the
following parameters: 1 missed cleavage, carbamidomethyla-
tion of Cys as a ﬁxed modiﬁcation, acetylation of protein N-ter
and oxidation of Met as variable modiﬁcations, MS tolerance at
5 ppm and MS/MS tolerance at 0.5 daltons, and a protein
list compilation by Protein Extractor (University of Alberta,
Alberta, Canada). At least 2 peptides with a P value less than
.05 (score, 20) were required for protein validation. With
these parameters, the false-discovery rate was less than 1%.
Yeast Two-Hybrid Screen
Yeast 2-hybrid screening was performed with the UL-
TImate Y2HTM platform (Hybrigenics, Paris, France) on a
human placenta cDNA library as prey, with human full-
length SASH1 (aa1–1247) as bait, cloned in a pB27
plasmid (N-LexA-bait-C fusion; Hybrigenics), according to
published protocols.51 The number of processed clones was
447, and 65 million interactions were analyzed. A conﬁ-
dence score previously shown to correlate with the biolog-
ical signiﬁcance of the interactions (predicted biological
score) was attributed to each interaction, essentially as
described elsewhere.52,53 This score (the predicted biolog-
ical score) is based ﬁrst on a local score, considering the
redundancy and independency of prey fragments, as well as
the distribution of reading frames and stop codons in
overlapping fragments. Second, a global score measures the
interactions found in all the screens performed at Hybri-
genics using the same library. The global score represents
the probability of an interaction being nonspeciﬁc. Only hits
from the highest conﬁdence categories were selected for
further analysis, from A (highest conﬁdence, 15 hits), B
(high conﬁdence, 9 hits), to C (good conﬁdence, 7 hits), and
all other categories (D to F, lowest conﬁdence, 52 hits in
total) were discarded from further analysis. Hits from cat-
egories A–C were veriﬁed independently for their presence
in co-immunoprecipitation/mass spectrometry experi-
ments, and curated manually for the number of EMT-related
articles by searching PubMed for “<gene name> and EMT.”
Dynamic Mass Redistribution–Based
Afﬁnity Measurement
The afﬁnity between SASH1 and CRKL was assessed
using a peptide corresponding to the CRKL binding
sequence within SASH1 (aa982–991, QPPPVPAKKS, syn-
thesized by JPT Peptide Technologies, Berlin, Germany), and
the recombinant SH3N of CRKL. The SH3N domain was
fused to a hexahistidine-tag at the C-terminus and puriﬁed
from Escherichia coli BL21 Star DE3 (Thermo Fisher Scien-
tiﬁc). Assay plates (Enspire-LFB, 384-well High Sensitivity,
User-Activated Biochemical Plates, Corning Epic System;
Corning) were activated with N-hydroxysulfosuccinimide
and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide for 30
minutes at room temperature. After washing 4 times with
25 mL ddH2O, 15 mL of the puriﬁed domain at a concen-
tration of 25 mg/mL in 20 mmol/L sodium acetate (pH 5.0)
was added to each well and allowed to immobilize overnight
at 4C. The plate then was washed 4 times with 15 mL PBS
(pH 7.4), containing 0.005% Tween-20, and equilibrated to
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measured using the Enspire Multimode Plate Reader (Per-
kinElmer, Waltham, MA). Volumes of 15 mL peptide solution
at different concentrations then were added and the ﬁnal
read was performed. Response was calculated by subtract-
ing the baseline from the ﬁnal peak wavelength.Orthotopic Mouse Model
HCT116 cells (parental, and clones S1 and S1C2) were
transduced with retroviral particles carrying a luciferase
encoding vector (LPP-hLUC-Lv201-025-C; GeneCopoeia,
Rockville, MD). Cells were selected with 1 mg/mL puromycin
for 3 weeks. Bioluminescence of cultured cells was
measured in a luminometer (FLUOstar OPTIMA; BMG Lab-
tech GMBH, Ortenberg, Germany). Female SCID/beige mice
(Barcelona Biomedical Research Park, Barcelona, Spain)
were used at 8 weeks of age. All mice were housed under
speciﬁc pathogen-free conditions in mixed groups and in
accordance with institutional guidelines approved by the
Use Committee for Animal Care of the University of Santiago
de Compostela (Santiago de Compostela, Spain). For sur-
gery, mice were anesthetized under constant isoﬂurane
application. The cecum was exposed with an incision
through the abdominal wall. The luminal content was
carefully pushed away from the tip of the cecum and
approximately the ﬁrst 2 mm of the tip of the cecum then
was tied up using absorbable surgical sutures. Cells resus-
pended in ice-cold Matrigel were injected into the enclosed
cecal lumen (5  106 cells in 25 mL Matrigel). The cell/
Matrigel suspension was allowed to rigidify before the
surgical wound was closed. Mice were killed upon signs of
distress or weight loss greater than 10%, otherwise tumors
were allowed to grow for 34 days with regular daily follow-
up evaluation. Mice then were injected intraperitoneally
with 10 mL/g D-luciferine substrate (P/N 122796; Perki-
nElmer) before death. Spatially resolved luminescence
measurements were performed on whole dissected mice
with an IVIS Spectrum In Vivo Imaging System (Xenogen
Corp, Alameda, CA; Caliper Life Sciences, Inc, Hopkinton,
MA; PerkinElmer, Waltham, MA), and data were analyzed
using Living Image 3.1. In 2 of 6 mice injected with SASH1-
deﬁcient cells, primary tumors were barely developed,
obviously failing to attach to the mucosa. These mice were
excluded from further analysis.
Immunohistochemistry
Formalin-ﬁxed tissue samples from the orthotopic
xenograft experiments were embedded in parafﬁn, from
which 2-mm sections were generated. These sections were
deparafﬁnized in Roticlear (Carl Roth) 3 times for 10
minutes. Rehydration was performed with an ethanol
gradient before samples were boiled in citrate buffer (10
mmol/L, pH 6.0) at 94C for 20 minutes. After washing
with PBS containing 0.1% BSA, peroxidase activity was
blocked by incubating the samples in 3% H2O2 in methanol
for 5 minutes at room temperature. Samples were washed
3 times with PBS, 0.1% BSA, and then treated with 0.1%
Triton X-100 in PBS, 0.1% BSA for 5 minutes at roomtemperature. The tissue sections then were blocked with
10% goat serum in PBS, 0.1% BSA for 1 hour at room
temperature, before they were incubated with the primary
antibody in blocking solution overnight at 4C. As primary
antibodies, either anti–E-cadherin (ab40772; Abcam) or
anti-mitochondria (ab92824; Abcam) were used. The next
day, samples were washed 3 times with PBS, 0.1% BSA,
before they were incubated with the appropriate second-
ary anti-mouse or anti-rabbit antibody–horseradish-
peroxidase conjugate (EnVisionþ System; DAKO, Agilent,
Leuven, Belgium) for 1 hour at room temperature. Samples
were washed 3 times with PBS, and chromogen-substrate
mixture (DAKO) was added for 8 minutes at room tem-
perature. After washing in ddH2O, sections were counter-
stained with hematoxylin for 5 minutes at room
temperature, washed again with H2O, and mounted with
gelatin. Images were acquired with a Zeiss Axiolab micro-
scope (Carl Zeiss).
Analysis of Human Tissue Samples
Seventy-six patients with stage III primary colon cancer
were analyzed, who underwent curative surgery (R0) and
provided informed consent for analysis of their tissue and
data before surgery at the Department of Surgery (Technical
University of Munich, Munich, Germany). The tissue was
shock-frozen immediately after resection. Clinicopathologic
characteristics of the patients are summarized in Figure 7E.
Patients with documented local recurrence were not
included in this study to circumvent putative bias by poor
surgical technique. Ethical and data protection standards of
this study were ensured by supervision of the Ethics Com-
mittee of the Faculty of Medicine (Technical University of
Munich), which approved the study (#1926/07, #5428/12).
Tumor-speciﬁc overall survival and recurrence-free survival
(ie, distant metastasis-free survival) was considered as the
primary end point for risk prediction. Statistical evaluation
was performed using IBM SPSS Statistics software version
20.0 (SPSS, Inc, Chicago, IL). To derive optimal cut-off values
of gene expression levels (SASH1, 0.29; CRKL, 0.44), maxi-
mally selected log-rank statistics performed by R Software
version 2.13.0 (R Foundation for Statistical Computing,
Vienna, Austria) were used. To consider multiple test issues
within these analyses, the R-function maxstat.test was used.
Survival analysis was performed using Kaplan–Meier esti-
mates. All statistical tests were performed 2-sided, and the
signiﬁcance level was set at 0.05. No correction of P values
was applied to adjust for multiple test issues. However,
results of all statistical tests being conducted were thor-
oughly reported so that an informal adjustment of P values
could be performed while reviewing the data. The Cancer
Genome Atlas TCGA data set was analyzed for prognostic
association of SASH1 and CRKL genes with the cBioPortal
platform, consisting of 213 fully sequenced colorectal can-
cer samples with available follow-up documentation.29,30Statistical Evaluation
Statistical analysis was performed with GraphPad Prism
6.01 (GraphPad Software, San Diego, CA). All error bars
2019 SASH1 Blocks EMT Through Inhibition of CRKL 51represent the SD. Statistical tests, P values, and sample size
are indicated in ﬁgure legends.References
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